相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
Hye Joung Choi et al.
GYNECOLOGIC ONCOLOGY (2019)
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga et al.
GYNECOLOGIC ONCOLOGY (2019)
PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
Aziz Ur Rehman Aziz et al.
BIOMOLECULES (2018)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A. Ledermann et al.
LANCET (2016)
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois et al.
LANCET ONCOLOGY (2016)
Prediction of chemo-response in serous ovarian cancer
Jesus Gonzalez Bosquet et al.
MOLECULAR CANCER (2016)
Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.
Brittany Anne Davidson et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Seiji Mabuchi et al.
GYNECOLOGIC ONCOLOGY (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
Pavla Brachova et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data
Jesus Gonzalez Bosquet et al.
CANCER RESEARCH (2014)
Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently?
Michael L. Friedlander et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
W. Yan et al.
ONCOGENE (2013)
Pattern discovery and cancer gene identification in integrated cancer genomic data
Qianxing Mo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Independent transcriptional reprogramming and apoptosis induction by cisplatin
Lorenzo Galluzzi et al.
CELL CYCLE (2012)
Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma
Atsuko Katagiri et al.
MODERN PATHOLOGY (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience
J. Alexandre et al.
ANNALS OF ONCOLOGY (2010)
Regularization Paths for Generalized Linear Models via Coordinate Descent
Jerome Friedman et al.
JOURNAL OF STATISTICAL SOFTWARE (2010)
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis
Ronglai Shen et al.
BIOINFORMATICS (2009)
Symptom Control in Patients With Recurrent Ovarian Cancer Measuring the Benefit of Palliative Chemotherapy in Women With Platinum Refractory/Resistant Ovarian Cancer
Michael Friedlander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
K. Oikonomopoulou et al.
BRITISH JOURNAL OF CANCER (2008)
Wnt-signaling and senescence A tug of war in early neoplasia?
Peter D. Adams et al.
CANCER BIOLOGY & THERAPY (2008)
How do real tumors become resistant to cisplatin?
Piet Borst et al.
CELL CYCLE (2008)
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Keren Levanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Critical pathways in cellular senescence and immortalization revealed by gene expression profiling
A. L. Fridman et al.
ONCOGENE (2008)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy
Yingye Zheng et al.
CLINICAL CANCER RESEARCH (2007)
The KEGG resource for deciphering the genome
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2004)
Circular binary segmentation for the analysis of array-based DNA copy number data
AB Olshen et al.
BIOSTATISTICS (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
